| 1 |
Fatty Acid Conjugated Chalcones as Tubulin Polymerization Inhibitors: Design, Synthesis, QSAR, and Apoptotic and Antiproliferative Activity |
26/4/2023 |
| 2 |
Nature-inspired chalcone-functionalized paracetamol derivatives as potential anticancer leads: synthesis, biological evaluation, apoptotic mechanisms, and in silico docking studies |
2026 |
| 3 |
Analysis of CD22 cis-ligands using a synthetic sialoside binding to CD22 with ultra-high affinity |
2025 |
| 4 |
CDK2 Inhibitors: Rationally Directed Discovery of a Novel Potent Lead derived from Cyclohepta[e]thieno[2,3-b]pyridine |
2025 |
| 5 |
Design, synthesis, and antiproliferative activity of new 2-amino-pyrano[3,2-c]quinoline-3- carbonitriles as potential EGFR, BRAFV600E, and HER-2 inhibitors |
2025 |
| 6 |
Design, synthesis, and antiproliferative activity of new 5-ethylsulfonylindazole- 3-carbohydrazides as dual EGFR/VEGFR-2 kinases inhibitors |
2025 |
| 7 |
Design, Synthesis, and Antiproliferative Activity of Novel Indole/1,2,4-Triazole Hybrids as Tubulin Polymerization Inhibitors |
2025 |
| 8 |
Design, Synthesis, and Biological Evaluation of Novel Benzimidazole/Schiff Base Hybrid Derivatives With Potential Biological Activities |
2025 |
| 9 |
Design, synthesis, and characterization of novel 5- ethylsulfonyl-indazole-3-carboxamides as dual VEGFR-2 and EGFR inhibitors: apoptotic antiproliferative and immunomodulatory evaluations |
2025 |
| 10 |
Design, synthesis, and computational studies of novel pyrazoline-based dual EGFR/HER-2 inhibitors with apoptotic antiproliferative activity |
2025 |
